Avrobio, Inc.
(NASDAQ : AVRO)

( )
AVRO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.50%101.030.0%$1484.62m
BIIBBiogen, Inc. -0.32%243.381.7%$644.21m
AMGNAmgen, Inc. -0.43%222.221.3%$567.12m
GILDGilead Sciences, Inc. -0.37%59.891.0%$536.35m
VRTXVertex Pharmaceuticals, Inc. 1.24%217.871.9%$474.35m
REGNRegeneron Pharmaceuticals, Inc. 0.94%523.612.7%$454.22m
BNTXBioNTech SE 2.34%106.500.0%$445.38m
ILMNIllumina, Inc. 0.35%301.853.5%$377.50m
NVAXNovavax, Inc. 8.59%93.9892.9%$336.34m
EXASEXACT Sciences Corp. 4.61%120.5419.6%$304.90m
MGENMiragen Therapeutics, Inc. 0.35%17.300.7%$272.94m
SRRKScholar Rock Holding Corp. -1.57%41.400.0%$245.77m
APVOAptevo Therapeutics, Inc. -0.18%45.5518.3%$228.01m
SGENSeagen Inc. -3.08%168.075.8%$173.40m
ALXNAlexion Pharmaceuticals, Inc. 1.01%122.612.0%$162.56m

Company Profile

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA.